Answers are grounded in this paper and cite their sources.
Structured Abstract Objective Significant coronary artery disease (CAD) remains a relative contraindication to lung transplantation (LTx) affecting ∼10% of candidates. Contemporary percutaneous coronary intervention (PCI) has broadened eligibility, but optimal dual antiplatelet therapy (DAPT) duration remains unclear. AHA/ACC recommend ≥3 months DAPT after PCI for patients undergoing high bleeding risk surgeries to reduce major adverse cardiovascular events (MACE); however, delaying urgent LTx poses significant mortality risk. This study assesses safety of ADAPT (<3 months) in LTx candidates with pre-transplant PCI. Methods In this retrospective study (2011-2025), P2Y12 inhibitors were discontinued pre-listing/transplantation, and aspirin was continued perioperatively. 43 patients were stratified by DAPT duration (<3, 3–6, >6 months). The primary endpoint was MACE (stent thrombosis, myocardial infarction (MI), cardio/cerebrovascular events, cardiac death). Secondary endpoints—survival, bleeding, venous thromboembolism (VTE)—were evaluated across DAPT durations and via propensity-matched comparison with no-aspirin cohort. Results Abbreviated DAPT (ADAPT) exhibited no increased MACE (p>0.99), bleeding (p=0.82), and VTE (PE p>0.99, DVT p>0.76). One-year survival was 100% in <3- and 3-6-month groups, and 96% in >6-month group. Five-year survival remained comparable (p=0.15), with mortalities exclusively non-cardiovascular in etiology. DAPT ≤2 months (n=6) also maintained 100% 1-year survival. Perioperative aspirin demonstrated no excess bleeding risk (p=0.51) or protection against VTE events (PE p>0.99, DVT p>0.99). Conclusions In selected patients with concomitant CAD requiring urgent LTx, ADAPT (<3 months) with perioperative aspirin monotherapy can safely balance ischemic and bleeding risks. Aggressive ≤2-month DAPT may also be reasonable. Perioperative aspirin conferred no additional bleeding risk or protection against VTE events.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: